Tevogen Bio (NASDAQ:TVGN) Issues Earnings Results

Tevogen Bio (NASDAQ:TVGN) announced its quarterly earnings results on Tuesday. The company reported ($2.08) EPS for the quarter, missing the consensus estimate of ($0.06) by ($2.02), FiscalAI reports.

Tevogen Bio Price Performance

TVGN stock traded up $0.23 on Tuesday, reaching $4.52. 37,259 shares of the company were exchanged, compared to its average volume of 54,350. The firm has a market capitalization of $18.31 million, a PE ratio of -0.48 and a beta of -0.76. Tevogen Bio has a 12 month low of $4.14 and a 12 month high of $75.50. The stock’s fifty day moving average price is $11.05 and its 200 day moving average price is $21.03.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on TVGN shares. D. Boral Capital lowered shares of Tevogen Bio from a “buy” rating to a “hold” rating in a research note on Wednesday, March 4th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tevogen Bio in a research report on Wednesday, January 21st. Finally, Wall Street Zen lowered Tevogen Bio to a “strong sell” rating in a research note on Saturday, March 21st. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Reduce” and a consensus target price of $100.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Goldman Sachs Group Inc. lifted its stake in shares of Tevogen Bio by 126.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 273,694 shares of the company’s stock valued at $91,000 after buying an additional 152,572 shares during the period. Deutsche Bank AG increased its stake in Tevogen Bio by 304.1% during the fourth quarter. Deutsche Bank AG now owns 173,734 shares of the company’s stock valued at $57,000 after acquiring an additional 130,738 shares during the period. Finally, Bridgeway Capital Management LLC raised its holdings in Tevogen Bio by 66.7% in the 3rd quarter. Bridgeway Capital Management LLC now owns 82,500 shares of the company’s stock valued at $65,000 after acquiring an additional 33,000 shares in the last quarter.

Tevogen Bio Company Profile

Tevogen Bio plc (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company’s lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML).

In addition to its lead program in AML, Tevogen Bio’s pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections.